Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

Nature

Volumn 521, Issue 7550, 2015, Pages 94-98

  Shalapour, Shabnam ^a,b   Font Burgada, Joan ^a,b   Di Caro, Giuseppe ^a,b   Zhong, Zhenyu ^a,b   Sanchez Lopez, Elsa ^a,b   Dhar, Debanjan ^a,b   Willimsky, Gerald ^c   Ammirante, Massimo ^a,b   Strasner, Amy ^a,b   Hansel, Donna E ^b   Jamieson, Christina ^d   Kane, Christopher J ^d   Klatte, Tobias ^e   Birner, Peter ^e   Kenner, Lukas ^e,f   Karin, Michael ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ALPHA SMOOTH MUSCLE ACTIN; CASPASE 3; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CXCL13 CHEMOKINE; GAMMA INTERFERON; HISTONE H2AX; IMMUNOGLOBULIN A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 21; INTERLEUKIN 6; LYMPHOTOXIN ALPHA BETA; OXALIPLATIN; PROGRAMMED DEATH 1 LIGAND 1; SMAD2 PROTEIN; SMAD3 PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CD274 PROTEIN, MOUSE; CXCL13 PROTEIN, HUMAN; I KAPPA B KINASE; PLATINUM COMPLEX; TRANSFORMING GROWTH FACTOR BETA;

CHEMOTHERAPY; CYTOLOGY; DRUG; GENE EXPRESSION; IMMUNOASSAY; TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ERADICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CANCER STEM CELL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CHEMOKINE CXCL13; HUMANS; I-KAPPA B KINASE; IMMUNOGLOBULIN A; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; PLASMA CELLS; PROSTATIC NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84929085260     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14395     Document Type: Article

References (57)

1. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10 (2013).
2. Schietinger, A.&Greenberg, P. D. Tolerance andexhaustion: definingmechanisms of T cell dysfunction. Trends Immunol. 35, 51-60 (2014).
3. Zitvogel, L., Galluzzi, L., Smyth, M. J. & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88 (2013).
4. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72 (2013).
5. Ammirante,M., Luo, J. L., Grivennikov, S.,Nedospasov, S.& Karin,M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature464, 302-305 (2010).
6. Ammirante, M. et al. An IKKa-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev. 27, 1435-1440 (2013).
7. Lee, J. L. et al. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. Br. J. Cancer 110, 2472-2478 (2014).
8. Kaplan-Lefko, P. J. et al. Pathobiology of autochthonous prostate cancer in a preclinical transgenic mouse model. Prostate 55, 219-237 (2003).
9. Watson, P. A. et al. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 65, 11565-11571 (2005).
10. Ammirante, M.,Shalapour, S., Kang, Y.,Jamieson, C. A.&Karin,M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumormyofibroblasts. Proc. Natl Acad. Sci. USA 111, 14776-14781 (2014).
11. Cerutti, A. The regulation of IgA class switching. Nature Rev. Immunol. 8, 421-434 (2008).
12. Yoshizaki, A. et al. Regulatory B cells control T-cell autoimmunity through IL-21- dependent cognate interactions. Nature 491, 264-268 (2012).
13. Affara, N. I. et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25, 809-821 (2014).
14. Yu, Y. P. et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790-2799 (2004).
15. Luo, J. L. et al.Nuclear cytokine-activated IKKa controls prostate cancer metastasis by repressing Maspin. Nature 446, 690-694 (2007).
16. Doi, T. et al. IgA plasma cells express the negative regulatory co-stimulatory molecule programmed cell death 1 ligand and have a potential tolerogenic role in the intestine. Biochem. Biophys. Res. Commun. 425, 918-923 (2012).
17. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. & Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57, 3325-3330 (1997).
18. Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17-27 (1994).
19. Xiao, S. et al. Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Igmucin 1 (Tim-1) mucin domain-mutant mice. Proc. Natl Acad. Sci. USA 109, 12105-12110 (2012).
20. Kang, H. S. et al. Signaling via LTbR on the lamina propria stromal cells of the gut is required for IgA production. Nature Immunol. 3, 576-582 (2002).
21. Feng, T., Elson, C. O. & Cong, Y. Treg cell-IgA axis in maintenance of host immune homeostasis with microbiota. Int. Immunopharmacol. 11, 589-592 (2011).
22. Shen, P. et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366-370 (2014).
23. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012).
24. Qin, Z. et al. B cells inhibit induction of T cell-dependent tumor immunity. Nature Med. 4, 627-630 (1998).
25. Olkhanud, P. B. et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting restingCD41 T cells to T-regulatory cells. Cancer Res. 71, 3505-3515 (2011).
26. Fremd, C., Schuetz, F., Sohn, C., Beckhove, P. & Domschke, C. B cell-regulated immune responses in tumor models and cancer patients. OncoImmunology 2, e25443 (2013).
27. Shah, N. Diagnostic significance of levels of immunoglobulin A in seminal fluid of patients with prostatic disease. Urology 8, 270-272 (1976).
28. Schumacher, T. N., Kesmir, C. & van Buuren, M. M. Biomarkers in cancer immunotherapy. Cancer Cell 27, 12-14 (2015).
29. Shen, F. W. et al. Cloning of Ly-5 cDNA. Proc. Natl Acad. Sci. USA 82, 7360-7363 (1985).
30. Gingrich, J. R. et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56, 4096-4102 (1996).
31. Chen, J. et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int. Immunol. 5, 647-656 (1993).
32. Koh, D. R. et al. Less mortality but more relapses in experimental allergic encephalomyelitis in CD82/2 mice. Science 256, 1210-1213 (1992).
33. Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869-877 (1992).
34. Forrester, E. et al. Effect of conditional knockout of the type II TGF-b receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res. 65, 2296-2302 (2005).
35. Harriman, G. R. et al. Targeted deletion of the IgA constant region inmice leads to IgA deficiency with alterations in expression of other Ig isotypes. J. Immunol. 162, 2521-2529 (1999).
36. Porichis, F. et al. High-throughput detection ofmiRNAs and gene-specificmRNAat the single-cell level by flow cytometry. Nature Commun. 5, 5641 (2014).
37. Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573-1577 (2011).
38. Keren, Z. et al. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. Blood 117, 3104-3112 (2011).
39. Holzbeierlein, J. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes andmechanisms of therapy resistance. Am. J. Pathol. 164, 217-227 (2004).
40. LaTulippe, E. et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506 (2002).
41. Singh, D. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209 (2002).
42. Arredouani, M. S. et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin. Cancer Res. 15, 5794-5802 (2009).
43. Liu, P. et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 66, 4011-4019 (2006).
44. Grasso, C. S. et al. Themutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
45. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811-816 (2004).
46. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nature Genet. 39, 41-51 (2007).
47. Welsh, J. B. et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61, 5974-5978 (2001).
48. Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406 (2005).
49. Magee, J. A. et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61, 5692-5696 (2001).
50. Wallace, T. A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927-936 (2008).
51. Vanaja, D. K., Cheville, J. C., Iturria, S. J. & Young, C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877-3882 (2003).
52. Luo, J. H. et al. Gene expression analysis of prostate cancers. Mol. Carcinog. 33, 25-35 (2002).
53. Rhodes, D. R. et al.ONCOMINE: a cancer microarray databaseandintegrated datamining platform. Neoplasia 6, 1-6 (2004).
54. Di Caro, G. et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20, 2147-2158 (2014).
55. Woo, J. R. et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J. Transl. Med. 12, 30 (2014).
56. D'Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J. Am. Med. Assoc. 280, 969-974 (1998).
57. Czéh, M. et al. The immune response to sporadic colorectal cancer in a novel mouse model. Oncogene 29, 6591-6602 (2010).